XML 34 R19.htm IDEA: XBRL DOCUMENT v3.25.3
Note 11 - Segment Information
 6 Months Ended
Sep. 30, 2025
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 11. Segment Information

 

Segment information is prepared on the same basis used by our chief operating decision maker ("CODM"), our CEO, to assess segment performance, allocate resources, evaluate financial results, and make key operating decisions. Our four reportable segments are organized primarily by the nature of the goods and services they sell. Our CODM regularly reviews segment-level U.S. GAAP revenues and gross profit relative to forecasted and prior period amounts, as well as non-GAAP adjusted operating expense compared to budgeted amounts. Our CODM also regularly reviews non-GAAP organic revenues growth to support strategic planning and resource deployment.

 

The following tables set forth our segment information:

 

Three months ended September 30, 2025

 

Sterilization and Disinfection Control

  

Biopharmaceutical Development

  

Calibration Solutions

  

Clinical Genomics

  

Total

 

Revenues (a):

 $22,107  $13,920  $13,570  $11,140  $60,737 

Less

                    

Depreciation in cost of revenues

  461   66   112   152   791 

Amortization in cost of revenues

  140   375   -   192   707 

Other cost of revenues (b)

  6,636   5,350   5,223   4,699   21,908 

Total segment cost of revenues

  7,237   5,791   5,335   5,043   23,406 

Gross Profit (c)

 $14,870  $8,129  $8,235  $6,097  $37,331 

Reconciling items:

                    

Operating expense

                 $32,607 

Operating income

                  4,724 

Nonoperating expense, net

                  2,725 

Earnings before income taxes

                 $1,999 

 

Three months ended September 30, 2024

 

Sterilization and Disinfection Control

  

Biopharmaceutical Development

  

Calibration Solutions

  

Clinical Genomics

  

Total

 

Revenues (a):

 $22,205  $11,867  $12,262  $11,499  $57,833 

Less

                    

Depreciation in cost of revenues

  374   40   207   283   904 

Amortization in cost of revenues

  134   346   -   192   672 

Non-cash GKE inventory step-up amortization

  454   -   -   -   454 

Other cost of revenues (b)

  6,071   4,314   4,845   5,118   20,348 

Total segment cost of revenues

  7,033   4,700   5,052   5,593   22,378 

Gross Profit (c)

 $15,172  $7,167  $7,210  $5,906  $35,455 

Reconciling items:

                    

Operating expense

                 $31,947 

Operating income

                  3,508 

Nonoperating (income), net

                  (304)

Earnings before income taxes

                 $3,812 

 

 

Six months ended September 30, 2025

 

Sterilization and Disinfection Control

  

Biopharmaceutical Development

  

Calibration Solutions

  

Clinical Genomics

  

Total

 

Revenues (a):

 $47,517  $25,406  $25,920  $21,437  $120,280 

Less

                    

Depreciation in cost of revenues

  911   155   217   318   1,601 

Amortization in cost of revenues

  279   747   -   383   1,409 

Other cost of revenues (b)

  13,291   10,069   10,426   9,214   43,000 

Total segment cost of revenues

  14,481   10,971   10,643   9,915   46,010 

Gross Profit (c)

 $33,036  $14,435  $15,277  $11,522  $74,270 

Reconciling items:

                    

Operating expense

                 $66,482 

Operating income

                  7,788 

Nonoperating (income), net

                  (1,223)

Earnings before income taxes

                 $9,011 

 

 

Six months ended September 30, 2024

 

Sterilization and Disinfection Control

  

Biopharmaceutical Development

  

Calibration Solutions

  

Clinical Genomics

  

Total

 

Revenues (a):

 $45,162  $23,875  $24,063  $22,903  $116,003 

Less

                    

Depreciation in cost of revenues

  793   86   392   495   1,766 

Amortization in cost of revenues

  245   691   -   383   1,319 

Non-cash GKE inventory step-up amortization

  1,232   -   -   -   1,232 

Other cost of revenues (b)

  12,162   7,972   9,219   9,629   38,982 

Total segment cost of revenues

  14,432   8,749   9,611   10,507   43,299 

Gross Profit (c)

 $30,730  $15,126  $14,452  $12,396  $72,704 

Reconciling items:

                    

Operating expense

                 $63,616 

Operating income

                  9,088 

Nonoperating expense, net

                  1,371 

Earnings before income taxes

                 $7,717 

 

 

(a)

Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. Revenues as presented are consistent with GAAP measurement principles and our CODM's review of segment information.

 

(b)

Other segment cost of revenues for each reportable segment includes product costs, personnel costs (including stock-based compensation), and other manufacturing and overhead costs necessary to produce and sell our products and services, excluding depreciation, amortization and any non-cash inventory step-up amortization expense.

 (c)Gross profit as presented is consistent with GAAP measurement principles and our CODM's review of segment information.

 

 

The following table sets forth inventories by reportable segment. Our CODM is not provided with and does not regularly review any other segment asset information.

 

  

September 30,

  

March 31,

 
  

2025

  

2025

 

Sterilization and Disinfection Control

 $6,771  $5,545 

Biopharmaceutical Development

  5,715   4,934 

Calibration Solutions

  6,150   5,110 

Clinical Genomics

  9,103   9,776 

Total inventories

 $27,739  $25,365